WIPO logo
Мобильная версия | Deutsch | English | Español | Français | 日本語 | 한국어 | Português | 中文 | العربية |
PATENTSCOPE

Поиск по международным и национальным патентным фондам
World Intellectual Property Organization
PATENTSCOPE будет недоступен в течение нескольких часов по причине технического обслуживания суббота 18.08.2018 в 09:00 CEST
Поиск
 
Просмотреть
 
Перевод
 
Настройки
 
Новости
 
Войти в систему
 
Помощь
 
Автоматизированный перевод
1. (WO2017217807) BIOMARKER COMPRISING NCKAP1 AS EFFECTIVE INGREDIENT FOR DIAGNOSING COLORECTAL CANCER OR FOR PREDICTING METASTASIS AND PROGNOSIS OF COLORECTAL CANCER
Новейшие библиограф. данные, касающиеся досье в Международном бюро    Отправить комментарий

№ публикации: WO/2017/217807 № международной заявки: PCT/KR2017/006326
Дата публикации: 21.12.2017 Дата международной подачи: 16.06.2017
МПК:
C12Q 1/68 (2006.01) ,G01N 33/50 (2006.01) ,G01N 33/574 (2006.01)
Заявители: UNIVERSITY OF ULSAN FOUNDATION FOR INDUSTRY COOPERATION[KR/KR]; 93 Daehak-ro Nam-gu Ulsan 44610, KR
THE ASAN FOUNDATION[KR/KR]; (Pungnap-dong), 88, Olympic-ro 43-gil Songpa-gu Seoul 05505, KR
Изобретатели: CHOI, Eun Kyung; KR
JEONG, Seong-Yun; KR
SONG, Si Yeol; KR
LEE, Jae Hee; KR
Агент: TAEBAEK INTELLECTUAL PROPERTY LAW FIRM; #601 Innoplex 1 cha, 151Gasandigital 1-ro Geumcheon-gu Seoul 08506, KR
Дата приоритета:
10-2016-007502416.06.2016KR
Название (EN) BIOMARKER COMPRISING NCKAP1 AS EFFECTIVE INGREDIENT FOR DIAGNOSING COLORECTAL CANCER OR FOR PREDICTING METASTASIS AND PROGNOSIS OF COLORECTAL CANCER
(FR) BIOMARQUEUR COMPRENANT LA NCKAP1 EN TANT QU'INGRÉDIENT EFFICACE POUR LE DIAGNOSTIC DU CANCER COLORECTAL OU POUR LA PRÉDICTION DE MÉTASTASES ET LE PRONOSTIC DU CANCER COLORECTAL
(KO) NCKAP1을 유효성분으로 포함하는 대장암 진단 또는 대장암 전이 예후 예측용 바이오마커 조성물
Реферат: front page image
(EN) The present invention relates to a biomarker composition comprising NCK-Associated Protein 1 (NCKAP1) as an effective ingredient for diagnosis of colorectal cancer or for prediction of the metastasis and prognosis of colorectal cancer. In brief, new colorectal cancer target candidates were excavated by massive gene expression analysis in bloods of human colorectal cancer tissue-transplanted mouse models, and were experimentally assayed by downregulatng the expression of the target candidate genes in a colorectal cancer cell line. Through the experiment, the overexpression of NCKAP1 in blood and tissues of colorectal cancer patients, and the suppression of cancer cell migration, infiltration, and metastasis upon the downregulation of NCKAP1 were observed, with the consequent possibility confirmation of NCKAP1 for use as a novel colorectal cancer target. Therefore, effective use can be made of an expression level of NCKAP1 in colorectal cancer diagnosis, and of a NCKAP1 gene expression inhibitor as an effective ingredient in a pharmaceutical composition for the therapy of cancer or for the inhibition of cancer metastasis.
(FR) La présente invention concerne une composition de biomarqueur comprenant la protéine 1 associée à NCK (NCKAP1) en tant qu'ingrédient actif pour le diagnostic du cancer colorectal ou pour la prédiction de la métastase et le pronostic du cancer colorectal. En résumé, de nouveaux candidats cibles du cancer colorectal ont été excavés par une analyse massive de l'expression génétique dans les sangs de modèles de souris transplantés par le tissu du cancer colorectal humain, et ont été testés de manière expérimentale par régulation négative de l'expression des gènes cibles candidats dans une ligne de cellules de cancer colorectal. Par le biais de l'expérience, la surexpression de NCKAP1 dans le sang et les tissus de patients atteints du cancer colorectal, et la suppression de la migration, l'infiltration et la métastase des cellules cancéreuses lors de la régulation négative de NCKAP1 ont été observées, avec la possibilité de confirmation de la NCKAP1 pour une utilisation en tant que nouvelle cible de cancer colorectal. Par conséquent, on peut utiliser efficacement un niveau d'expression de NCKAP1 dans le diagnostic du cancer colorectal, et un inhibiteur de l'expression du gène NCKAP1 en tant qu'ingrédient efficace dans une composition pharmaceutique pour le traitement du cancer ou pour l'inhibition de métastases cancéreuses.
(KO) 본 발명은 NCKAP1(NCK-Associated Protein 1)을 유효성분으로 포함하는 대장암 진단 또는 대장암 전이 예후 예측용 바이오마커 조성물에 관한 것으로서, 구체적으로 인체 대장암 조직 이식 마우스 모델의 혈액에서 대량 유전자 발현 분석을 통해 신규한 대장암 표적 후보를 발굴하였고, 이를 대장암 세포주 내 표적 후보 유전자 발현 억제를 통해 실험적 검증을 하였다. 이를 통해 대장암 환자 혈액 및 조직에서 NCKAP1이 과발현되고, NCKAP1의 억제에 의한 암세포의 이동, 침윤 및 전이가 저해됨을 관찰하고, 신규한 대장암 표적으로서 NCKAP1의 가능성을 확인하였다. 따라서 NCKAP1의 발현 수준을 이용한 대장암 진단과 유전자 발현 억제제를 암의 치료 또는 암 전이 억제용 약학적 조성물의 유효성분으로 유용하게 이용할 수 있다.
Указанные государства: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Евразийская патентная организация (AM, AZ, BY, KG, KZ, RU, TJ, TM)
Европейское патентное ведомство (ЕПВ) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Язык публикации: Корейский (KO)
Язык подачи: Корейский (KO)